Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/3/2026, 12:00:00 AM
Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.
Korean Translation
EULAR 2026 학회에서 UPLIZNA의 새로운 3상 데이터를 발표함. 치료를 지속한 IgG4 관련 질환 환자에서 1년간 재발률 0%를 기록함. 긍정적인 임상 데이터는 시장 점유율 확대에 기여하므로 중간 중요도로 분류함, 예상됨.
Related Recent Events
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release is scheduled. This event is estimated to have a price impact of at least 1%.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 earnings results on August 5, 2026; a medium impact is expected as quarterly results are key performance indicators, scheduled.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled. Analysts forecast an EPS of approximately $1.63 to $1.66 forecasted. Low importance estimated: historical price reaction to earnings is typically 1-5%.
8/3/2026, 12:00:00 AM
The Cigna Group (CI) · Earnings Release
Second quarter 2026 financial results are scheduled to be released. This recurring financial event is estimated to have a medium price impact of at least 5% based on historical volatility scheduled.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM